Molecularly targeted therapies for breast cancer

Cancer Control

Volumn 12, Issue 2, 2005, Pages 73-81

  Hobday, Timothy J ^b   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANASTROZOLE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; CANERTINIB; CAPECITABINE; CARBOPLATIN; CGP 69846A; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EVEROLIMUS; EXEMESTANE; FARNESYL TRANS TRANSFERASE; FLT3 LIGAND; GEFITINIB; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PERTUZUMAB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ARTERY THROMBOSIS; BREAST CANCER; CANCER CELL; CANCER RISK; CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG TOLERANCE; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; HEADACHE; HEART DISEASE; HORMONAL THERAPY; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MEDICAL LITERATURE; NEPHROTIC SYNDROME; PATIENT SELECTION; RASH; REVIEW; THROMBOEMBOLISM;

EID: 18444394024     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480501200202     Document Type: Review

References (51)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist. 2003;8:335-341.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
4. Extra JM, Cognetti F, Chan S, et al. First-line trastuzumab (Herceptin) plus docetaxel versus docetaxel alone in women with HER2-positive metastatic breast cancer (MBC): results from a randomised phase II trial (M77001). Breast Cancer Res Treat. 2003;82(suppl 1):S47. Abstract 217.
5. Early Breast Cancer Trialists' Colaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
6. Ingle JN, Twito DI, Schaid DJ, et al. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. J Clin Oncol. 1988;6:825-831.
7. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: results of two randomized trials designed for combined analysis. Cancer. 2001;92:2247-2258.
8. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808-3816.
9. Smith I, Dowsett M, on behalf of the IMPACT Trialists. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Can Res Treat. 2003;82:S6. Abstract 1.
10. Baum M, Budzar AU, Cuzik J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131-2139. Erratum in: Lancet. 2002;360: 1520.
11. Dowsett M, on behalf of the ATAC Trialists' Group. Analysis of time to recurrence in the ATAC (arimedex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Can Res Treat. 2003;82:S7. Abstract 4.
12. Atalay G, Cardoso F, Awada A, et al. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol. 2003;14:1346-1363.
13. Lin NU, Winer EP. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res. 2004;6:204-210.
14. Emens LA, Davidson NE. Trastuzumab in breast cancer. Oncology (Huntingt). 2004;18:1117-1128.
15. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
16. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
17. Pegram MD, Konecny GE, O'Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004;96:739-749.
18. Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Updated efficacy and safety analyses of 3-weekly Herceptin® monotherapy in women with HER2-positive metastatic breast cancer: results from twelve months of follow-up to a phase II study. Breast Can Res Treat. 2004;88(suppl 1):S126. Abstract 3042.
19. Albain K, Elledge R, Gradishar WJ, et al. Open-label, phase II, multicenter trial of ZD1839 ("Iressa") in patients with advanced breast cancer. Breast Can Res Treat. 2002;76:S33. Abstract 20.
20. Robertson JFR, Gutteridge E, Cheung KL, et al. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM) resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study. Proc Annu Meet Am Soc Clin Oncol. 2003;22:7. Abstract 23.
21. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib (ZD 1839) in patients with advanced breast cancer. Proc Annu Meet Am Soc Clin Oncol. 2003;22:7. Abstract 24.
22. Winer E, Cobleigh M, Dickler M, et al. Phase II multicenter study to evaluate the efficacy and safety of Tarceva™ (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Can Res Treat. 2002;76:S115. Abstract 445.
23. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
24. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787-2799.
25. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001;1:85-94.
26. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and down-stream Erk1/2 and AKT pathways. Oncogene. 2002;21:6255-6263.
27. Burris H, Hurwitz H, Dees C, et al. EGF10004: a randomized, multicenter, phase Ib study of the safety, biologic activity and clinical efficacy of the dual kinase inhibitor GW572016. Breast Can Res Treat 2003;82. Abstract 39.
28. Maung K. Inhibition of ErbB1 and ErbB2 by lapatinib ditosylate, a dual kinase inhibitor: promising activity in pretreated advanced breast cancer. Clin Breast Cancer. 2004;4:398-400.
29. Blackwell KL, Kaplan EH, Franco SX, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol. 2004;22(14S):3006. Abstract.
30. Price N, Reddy GK, Tyagi P. Highlights from Third Annual Future of Breast Cancer: An International Congress. Clin Breast Cancer. 2004;5:172-176.
31. Agus DB, Gordon M, Taylor C, et al. Clinical activity in a phase I trial of HER-2-targeted rhuMAb2C4 (pertuzumab) in patients with advanced solid malignancies (AST). Proc Annu Meet Am Soc Clin Oncol. 2003;22:192. Abstract 771.
32. Allen LF, Eiseman IA, Fry DW, et al. CI-1033, an Irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol. 2003;30(5 suppl 16):65-78.
33. Arteaga CL, O'Neil A, Moulder SL, et al. ECOG1100: a phase I-II study of combined blockade of the erbB receptor network with trastuzmab and gefitinib ("Iressa") in patients (pts) with HER2-overexpressing metastatic breast cancer (met br ca). Breast Can Res Treat 2004;88:S15. Abstract 25.
34. Burris III HA, Storniolo AM, Overmoyer EA, et al. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. Breast Can Res Treat. 2004;88:S126. Abstract 3043.
35. Arpino G, Weiss H, Wakeling AE, et al. Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition. Breast Can Res Treat. 2004;88:S15. Abstract 23.
36. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84:1875-1887.
37. Syed S, Rowinsky E. The new generation of targeted therapies for breast cancer. Oncology (Huntingt). 2003;17:1339-1356.
38. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
39. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003;30:117-124.
40. Miller KD, Chap LI, Holmes FA, et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-799.
41. de Bono JS, Tolcher AW, Rowinsky EK. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma. Semin Oncol. 2003;30(5 suppl 16):79-92.
42. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell. 1994;77:175-178.
43. Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol. 2003;21:2492-2499.
44. LoRusso PM, Adjei AA, Meyer MB, et al. A phase 1 clinical and pharmacologic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer. Proc Annu Meet Am Soc Clin Oncol. 2002;21:81a. Abstract 321.
45. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22:4456-4462.
46. Carraway H, Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res. 2004;6:219-224.
47. Campbell IG, Russell SE, Choong DYH, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678-7681.
48. Chan S, Scheulen ME, Johnston S, et al. Final results of a phase 2 study of single-agent CCI-779 in locally advanced or metastatic breast cancer failing prior anthracycline and/or taxane regimens. Breast Can Res Treat. 2003;82:S82. Abstract 346.
49. Baselga J, Fumoleau P, Gil M, et al. Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. Proc Annu Meet Am Soc Clin Oncol. 2004;22(14S):544. Abstract.
50. Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol. 2002;14:628-634.
51. Brown J, Von Roenn J, O'Regan R, et al. A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol. 2004;22(14S):546. Abstract.